All News

Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss the distinct adverse effect profiles of HER2- and HER3-targeted antibody-drug conjugates—particularly the risk and management of interstitial lung disease—and offer practical guidance based on clinical trial data and treatment protocols.

Following a meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA announced its recommendation of COVID-19 vaccines targeting LP.8.1, a strain of the JN.1 variant that has become dominant in the US.

Pharmacists can counsel patients and educate the health care team about the risks of pharmacologically caused illnesses.

Pharmacists can make the process easier and more convenient for patients.

The approval is based on findings from the INSPIRE trial, where treprostinil demonstrated efficacy in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The authors are optimistic that GADD45A serves as a foundation for therapeutic approaches to slow the progression of heart failure.

RSV vaccines for pregnant women and infants require careful timing and administration.

These directives are typically used to shape federal agencies and manage employees in the executive branch.

The process teaches resilience, adaptability, and self-awareness.

Pharmacists improve outcomes by clarifying and delabeling inaccurate antibiotic allergies.

Christian John Lillis reflects on key insights from the 2025 Peggy Lillis Foundation C diff Summit, highlighting the critical role of pharmacists in infectious disease care, persistent challenges in patient outcomes, and the need for renewed investment in public health infrastructure and policy.

Market access offers pharmacists a dynamic career path.

Physical activity significantly enhanced quality of life and reduced fatigue and depression in patients with newly diagnosed multiple myeloma.

Orforglipron showed promising results in managing type 2 diabetes, offering a potential oral alternative to injectable treatments.

APOBEC3 mutagenesis emerges as a key factor in breast cancer treatment resistance, offering new avenues for targeted therapies and predictive biomarkers.

Christian John Lillis discusses the 2025 Peggy Lillis Foundation C diff Summit, emphasizing the enduring need for community-building among survivors, the importance of sustained public health advocacy, and the growing urgency to defend federal health agencies amid political and institutional uncertainty.

Interventions such as educational brochures, provider-delivered educational programs, and computerized reminders were found to help improve pneumococcal vaccine uptake in older adults.

Embedding a pharmacist in the dermatology clinic improved clinical and financial outcomes.

After 3 predictive mortality tools demonstrate inefficiency within older adults with advanced chronic kidney disease (CKD), the authors call for the development of tools tailored for this population.

Pharmacy students must have a comprehensive understanding of antiretrovirals to ensure efficiency and optimization of patients’ medical treatment.

Penalty is incarceration for multiple years and a massive fine.

This indication is for adult and pediatric patients aged 12 and older with plaque psoriasis of the scalp and body.

Mepolizumab gains FDA approval as a promising add-on therapy for COPD patients with eosinophilic phenotype, reducing exacerbation rates significantly.

Ranibizumab injection (Susvimo; Genentech) could offer long-lasting vision preservation and reduce the need for frequent injections in patients with diabetic retinopathy.

At the 2025 SPPCP Virtual Conference, Carolyn Hall, PharmD, BCPS, and Maria Felton Lowry, PharmD, BCPS, BCGP, presented a comprehensive and practical framework for pharmacy professionals to build effective, adaptable mentorship relationships.

Yuflyma gains FDA interchangeability with Humira, enhancing patient access to effective biosimilar treatments for various inflammatory conditions.

With each increase in lipoprotein(a) level in patients with atherosclerotic cardiovascular disease (ASCVD), there was a corresponding increase in risk of experiencing an ASCVD event.

Trastuzumab deruxtecan (T-DXd) yielded favorable outcomes and improved survival rates.

Cefepime-taniborbactam shows promise against resistant infections, but more studies are needed.